Positive news for our portfolio company, Oxford BioTherapeutics, it has announced a research collaboration with Kite, the global leader in cell therapy to evaluate five novel targets for a number of hematologic and solid tumor indications.
Positive news for our portfolio company, Oxford BioTherapeutics, it has announced a research collaboration with Kite, the global leader in cell therapy to evaluate five novel targets for a number of hematologic and solid tumor indications.